Norwegian Cancer Vaccine Reduces Lung Tumor Size

Norwegian Cancer Vaccine Reduces Lung Tumor Size

Targovax has preliminary clinical results showing its cancer vaccine can reduce the size of mesothelioma tumors in the lung. 

Targovax, a Norwegian biotech, has Phase I/II clinical results showing its peptide vaccine ONCOS-102 successfully reduced tumor sizes in 3 out of 6 patients after six months. One patient had a partial response. The disease stayed stable in the remaining two patients.

It’s important to note that the cancer vaccine was only tested in six patients, too small to draw conclusions, and the company will now see if the treatment’s effects hold up in a larger cohort of 30 patients.

Targovax’s ONCOS-102 works by injecting an oncolytic virus straight into the tumor, which specifically causes tumor cells to break open and release antigens. The patient’s immune system learns to recognize these antigens and attack other tumor cells.

Amgen’s Imlygic is currently the only oncolytic virus on the market. Targovax’s CMO Magnus Jäderberg believes this could be the start of an interesting trend.


Image by Billion Photos/Shutterstock

Previous post

Tackling the Legislation Muddle of Human Biological Samples

Next post

Novartis and Gilead's CAR-T Therapies Now Compete for the Same Cancer Patients

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.